Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. Its products include RYANODEX, BENDEKA and BELRAPZO. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Eagle Pharmaceuticals excels in 2022 with strong earnings growth

Eagle Pharmaceuticals' 2022 performance reflects strong earnings growth and operational efficiency, supported by key product sales and financial stability.
While facing challenges in managing expenses amidst investments, the company's strategic strengths lie in its product portfolio and financial resilience.
Opportunities for revenue growth and market expansion present avenues for Eagle Pharmaceuticals to further enhance its competitive position and drive future success.

Eagle Pharmaceuticals posts robust Q1 results, eyes strategic growth opportunities

Eagle Pharmaceuticals delivered a strong financial performance in Q1 2023, driven by key product sales and market share retention.
While facing challenges in expenses management, the company's solid cash position and growth strategies position it well for future opportunities.
Strategic initiatives like potential acquisitions and market expansion underscore Eagle Pharmaceuticals' commitment to sustained growth and innovation.

Eagle Pharmaceuticals beats Q2 estimates, eyes growth through strategic investments

Eagle Pharmaceuticals delivered a robust Q2 performance, exceeding expectations and demonstrating strong financial health. The company's strategic investments in R&D and commercial infrastructure position it well for future growth. Despite challenges and uncertainties, Eagle Pharmaceuticals remains optimistic about its continued growth trajectory and market prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WOODCLIFF LAKE, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2021.

Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results

WOODCLIFF LAKE, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 fourth quarter and full year financial results on Monday, March 7, 2022, before the market opens.

Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its novel product PEMFEXY™ (pemetrexed for injection). A branded alternative to ALIMTA®, Eagle's PEMFEXY is a ready-to-use liquid with a unique J-code approved to treat nonsquamous non-small cell lung cancer and mesothelioma. “We've spent the past several months building our inventory and are pleased that PEMFEXY will now be available to the

Eagle Pharmaceuticals Announces Commercial Availability of PEMFEXY™

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that AOP Orphan Pharmaceuticals GmbH, Member of the AOP Health Group, (“AOP Health”), with whom it entered into a licensing agreement in August 2021, has engaged with the U.S. Food and Drug Administration (“FDA”) to obtain alignment on the content and format of the pre-clinical and clinical data required to support a new drug application (“NDA”) seeking approval of Landio

Eagle Pharmaceuticals on Track to Support Submission of New Drug Application in Second Quarter 2022 for Landiolol, a Beta-1 Adrenergic Blocker

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced the commercial availability of its recently approved product, vasopressin, an A-rated generic alternative to Vasostrict®, with 180 days of marketing exclusivity. U.S. sales of Vasostrict totaled $890 million for the LTM ended September 30, 2021.1 On December 15, 2021, the U.S. Food and Drug Administration (“FDA”) approved Eagle's abbreviated new drug application (“ANDA”)

Eagle Pharmaceuticals Announces Commercial Availability of Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update for 2022: Near-Term Business Highlights: Vasopressin: The Company will begin shipping its recently approved vasopressin product on Monday, January 17, 2022, with 180 days of marketing exclusivity. This is an important product for Eagle, as Vasostrict® U.S. sales totaled $890 million for the LTM ended September 30, 2021. PEMFEXY™: On February 1, 2022, the

Eagle Pharmaceuticals Provides 2022 Business Update and Announces Launch of Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference as follows: Date: Wednesday, January 12, 2022 Time: 4:30PM ET Webcast: https://jpmorgan.metameetings.net/events/healthcare22/sessions/39965-eagle-pharmaceuticals/webcast?gpu_only=true&kiosk=tr

Eagle Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration has determined that the Company has maintained its 180 days of marketing exclusivity for its recently approved abbreviated new drug application (“ANDA”) for vasopressin. In August, the U.S. District Court for the District of Delaware held that Eagle's proposed vasopressin product does not infringe any of the patents Par Pharmaceu

Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin

BrightSphere Investment Group

Summit Hotel Properties

Meritage Homes

Summit Hotel (INN), Meritage Homes (MTH), Eagle Pharmaceuticals (EGRX) and BrightSphere (BSIG) could be some attractive bets if you are looking for high earnings yield picks.

4 High Earnings Yield Stocks Likely to Pay Off Big Time

Eagle Pharmaceuticals (EGRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Eagle Pharmaceuticals (EGRX) Upgraded to Buy: Here's What You Should Know

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle's recently approved vasopressin product. Par's appeal of the District Court's ruling on August 31, 2021, that Eagle's vasopressin product does no

Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved the Company's abbreviated new drug application (“ANDA”) for vasopressin. This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle's proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Compan

Eagle Pharmaceuticals Receives FDA Approval for Vasopressin

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as follows: Date:   Monday, November 22, 2021 Time/On Demand:   10:00AM ET Webcast:   https://pipersandler.zoom.us/rec/play/gKb-8Uf5FTyDI-TguX2M-ziZvOHQuT9LOFMBE7BTLwbNzRNQz-5dpn0wd3T7bdN8bc14RITsJSMvcBE

Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tariff on Q3 2021 Results - Earnings Call Transcript

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of -35.63% and -14.66%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Lag Estimates

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2021. Business and Recent Highlights: Entered into a worldwide licensing agreement for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe bacterial pneumonia in combination with traditional antibacterial drugs. Vasopressin up

Eagle Pharmaceuticals Reports Third Quarter 2021 Results

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: Date Tuesday, November 9, 2021 Time 8:30 a.m. ET Toll free (U.S.) 866-342-8591 International 203-518-9

Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021

Eagle Pharmaceuticals (EGRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Eagle Pharmaceuticals (EGRX) to Report a Decline in Earnings: What to Look Out for

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) will host an investor event, led by Scott Tarriff, Chief Executive Officer, and Judi Ng-Cashin, Chief Medical Officer, and will feature other guest speakers, to discuss the CAL02 opportunity, the current treatment landscape and the unmet medical need in treating patients with severe pneumonia as follows: Date           Thursday, September 9, 2021 Time           8:30 A.M. EDT Toll free (U

Reminder: Eagle Pharmaceuticals to Host CAL02 Investor Event on September 9, 2021

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at two upcoming investor conferences as follows: Conference: Morgan Stanley 19th Annual Global Healthcare Conference Date: Tuesday, September 14, 2021 Time: 2:00 p.m. ET Webcast: https://morganstanley.webcasts.com/starthere.jsp?ei=1488970&tp_key=c1aabe315b Conference:

Eagle Pharmaceuticals to Present at September Healthcare Conferences

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. District Court for the District of Delaware held that Eagle's proposed vasopressin product does not infringe any of the patents Par asserted against the Company. Eagle is first to file an Abbreviated New Drug Application (“ANDA”) referencing Vasostrict®, which had total U.S. sales of $786 million in 2020. In May 2018, Par sued Eagle for infringement of sever

Eagle Pharmaceuticals Wins Vasopressin Patent Trial

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,103,483, entitled “Formulations of Bendamustine.” Eagle is submitting the ‘483 patent for listing in the U.S. Food and Drug Administration's Orange Book for both BENDEKA® and BELRAPZO®. Eagle had asserted several Orange Book-listed patents against Slayback Pharma LLC, Apotex Inc. et al, M

Eagle Pharmaceuticals Granted Additional Patent for Bendamustine Franchise

WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has entered into a worldwide licensing agreement with Combioxin SA (“Combioxin”), a clinical-stage biotechnology company based in Epalinges, Switzerland, for the commercial rights to CAL02, a novel first-in-class antitoxin agent ready for Phase 2b/3 development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. Under the Agr

Eagle Pharmaceuticals Announces Worldwide Licensing Agreement with Combioxin SA for Phase 2b/3, Novel First-in-Class Antitoxin Agent CAL02 in Development for Combination Use with Antibiotics for the Treatment of Severe Pneumonia

Eagle Pharmaceuticals Inc (NASDAQ: EGRX) has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH for the commercial rights to its product, Landiolol, in the U.S.  Landiolol, a hospital emergency use product, is approved in Europe to treat non-compensatory sinus tachycardia and tachycardic supraventricular arrhythmias.

Eagle Pharmaceuticals In-Licenses US Rights For Emergency Hospital Product, Q2 Earnings Beat Consensus

Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tariff on Q2 2021 Results - Earnings Call Transcript

News for Eagle Pharmaceuticals Stock (EGRX)